Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

United Therapeutics (UTHR) EBIT (2016 - 2025)

United Therapeutics' EBIT history spans 17 years, with the latest figure at $356.7 million for Q4 2025.

  • For Q4 2025, EBIT changed 0.28% year-over-year to $356.7 million; the TTM value through Dec 2025 reached $1.5 billion, up 8.39%, while the annual FY2025 figure was $1.5 billion, 8.39% up from the prior year.
  • EBIT for Q4 2025 was $356.7 million at United Therapeutics, down from $388.5 million in the prior quarter.
  • Across five years, EBIT topped out at $388.5 million in Q3 2025 and bottomed at -$64.8 million in Q1 2021.
  • The 5-year median for EBIT is $313.8 million (2022), against an average of $279.5 million.
  • The largest annual shift saw EBIT crashed 138.87% in 2021 before it surged 544.44% in 2022.
  • A 5-year view of EBIT shows it stood at $169.8 million in 2021, then rose by 3.42% to $175.6 million in 2022, then skyrocketed by 48.12% to $260.1 million in 2023, then surged by 37.52% to $357.7 million in 2024, then dropped by 0.28% to $356.7 million in 2025.
  • Per Business Quant, the three most recent readings for UTHR's EBIT are $356.7 million (Q4 2025), $388.5 million (Q3 2025), and $364.5 million (Q2 2025).